Easy Find It Page
Easy Find It
Use Our Mobile Site
Use Our Mobile Site
Share This Website
The Sugar Trehalose
Free NEWS Letter
Affiliate Program
Untitled Document

Already an Affiliate? Click on the link below to access your account-

Affiliate Login

Endowment Book Store
The Trehalose Store
Endowment Store Front
Support The Endowment
Enter Amount:
We Accept
VisaMaster CardAmerican ExpressDiscoverssl lock
Download Store

Download Store

Download 7 Free Newsletters Plus Other Educational Materials

Main Menu
Home
- - - - - - -
Inside the Human Cell
The Sugar Trehalose
- - - - - - -
Sugar Science Forum
Glycomics Training
Interactive Glycomics Brochure
NEWS
7 FREE NEWSletters
HOT Links of Interest
- - - - - - -
Contact Us
Disclaimer
Sitemap
Educational e-textbook
Chapter One

Chapter One

FREE Sneek Peek
Chapter One


Evaluation Forms

Huntington’s General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Parkinson's General
Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Alzheimer / Dementia
General Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

Diabetic Health Evaluation
FORM for Trehalose
Nutritional Pilot Survey

General Public Health
Evaluation FORM for
Trehalose Nutritional
Pilot Survey (For General
Public without Huntington’s,
Alzheimer’s, or Parkinson’s.)

Who's Online
We have 22 guests online
Another Drug for Alzheimer's

Australia scientists work on anti-Alzheimer's pill

Australian mental health researchers have developed a once-a-day pill they believe might stop or slow the onset of Alzheimer's disease, with human trials expected within two months.

A 15-month trial on mice showed the drug called PBT2 reduced the amyloid protein, which many scientists believe causes Alzheimer's, by 60 percent within 24 hours, said researchers at The Mental Health Research Institute of Victoria.

Institute director George Fink said on Monday the drug attacked one of the root causes of Alzheimer's, a degenerative brain disease and the most common form of dementia, particularly in people over the age of 65.

"We think the drug can help best at an early phase of the disease to intervene and prevent further development of the disease -- nipping it in the bud," Fink told local radio.

The institute, which is working in collaboration with Prana Biotechnology Limited, made public its PBT2 trial results at the 10th International Conference on Alzheimer's Disease held in Madrid last week.

The institute and Prana said mice that took the drug orally showed improved memory performance after four days.

The tests required mice to remember the location of submerged platforms, requiring the mice to employ higher-level learning and spatial memory skills to successfully navigate a maze.

"It was demonstrated that PBT2 could quickly and significantly improve spatial memory -- an important barometer of cognitive function," said Prana in a statement.

The institute's tests also showed that PBT2 blocked the interaction between the amyloid protein and metals such as copper and zinc in the brain, stopping the development of Alzheimer's. Amyloid accumulates more rapidly in the presence of metals.

Human trials of PBT2 in patients with early Alzheimer's are expected to begin in Sweden within two months, said the institute.

Source Yahoo! NEWS